Monimus Capital Management LP acquired a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 137,058 shares of the company's stock, valued at approximately $1,621,000. Roivant Sciences comprises 1.5% of Monimus Capital Management LP's holdings, making the stock its 25th largest position.
Several other hedge funds have also made changes to their positions in ROIV. Monaco Asset Management SAM lifted its holdings in shares of Roivant Sciences by 35.0% during the 4th quarter. Monaco Asset Management SAM now owns 135,000 shares of the company's stock worth $1,597,000 after acquiring an additional 35,000 shares during the period. Commonwealth Equity Services LLC lifted its stake in Roivant Sciences by 24.2% during the fourth quarter. Commonwealth Equity Services LLC now owns 19,588 shares of the company's stock worth $232,000 after purchasing an additional 3,813 shares during the period. Thompson Siegel & Walmsley LLC lifted its stake in Roivant Sciences by 10.1% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 565,337 shares of the company's stock worth $6,688,000 after purchasing an additional 51,705 shares during the period. Swiss National Bank grew its stake in shares of Roivant Sciences by 0.9% in the 4th quarter. Swiss National Bank now owns 727,246 shares of the company's stock valued at $8,603,000 after purchasing an additional 6,200 shares during the period. Finally, Avantax Advisory Services Inc. bought a new stake in shares of Roivant Sciences in the 4th quarter valued at approximately $127,000. Institutional investors own 64.76% of the company's stock.
Insider Buying and Selling at Roivant Sciences
In related news, CAO Rakhi Kumar sold 227,500 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the transaction, the chief accounting officer now owns 163,264 shares in the company, valued at $1,702,843.52. This trade represents a 58.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was purchased at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the transaction, the director now owns 96,650,341 shares of the company's stock, valued at approximately $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 2,388,170 shares of company stock worth $27,612,299. Insiders own 7.90% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages recently commented on ROIV. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Roivant Sciences currently has a consensus rating of "Buy" and a consensus target price of $18.08.
Get Our Latest Stock Report on ROIV
Roivant Sciences Trading Up 1.8 %
Shares of Roivant Sciences stock traded up $0.19 during trading on Monday, reaching $10.85. The company's stock had a trading volume of 5,224,874 shares, compared to its average volume of 5,505,152. The stock has a 50-day moving average price of $10.81 and a two-hundred day moving average price of $11.50. The stock has a market capitalization of $7.74 billion, a P/E ratio of -72.33 and a beta of 1.26. Roivant Sciences Ltd. has a one year low of $9.76 and a one year high of $13.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, sell-side analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.
Roivant Sciences Company Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
See Also
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
